523 related articles for article (PubMed ID: 8673717)
21. Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0 T using high-relaxivity contrast agents.
Huang B; Liang CH; Liu HJ; Wang GY; Zhang SX
Acta Radiol; 2010 Feb; 51(1):78-84. PubMed ID: 19912078
[TBL] [Abstract][Full Text] [Related]
22. Gadobenate dimeglumine (Gd-DTPA) vs gadopentetate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio.
Pediconi F; Fraioli F; Catalano C; Napoli A; Danti M; Francone M; Venditti F; Nardis P; Passariello R
Radiol Med; 2003; 106(1-2):87-93. PubMed ID: 12951555
[TBL] [Abstract][Full Text] [Related]
23. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
Balci NC; Inan N; Anik Y; Erturk MS; Ural D; Demirci A
Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
[TBL] [Abstract][Full Text] [Related]
24. Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images.
Marin D; Iannaccone R; Catalano C; Passariello R
J Magn Reson Imaging; 2006 Sep; 24(3):690-4. PubMed ID: 16878304
[TBL] [Abstract][Full Text] [Related]
25. Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents.
Husarik DB; Gupta RT; Ringe KI; Boll DT; Merkle EM
Acad Radiol; 2011 Dec; 18(12):1549-54. PubMed ID: 21958599
[TBL] [Abstract][Full Text] [Related]
26. [NMR tomography of the liver with the new contrast agent Gd-BOPTA. The results of an in-vivo phase-I test].
Vogl TJ; Pegios W; Waitzinger J; Pirovano G; Balzer J; Lissner J
Rofo; 1992 May; 156(5):465-70. PubMed ID: 1596551
[TBL] [Abstract][Full Text] [Related]
27. [Magnetic resonance tomography of the hepatobiliary system: indications, limitations and outlook].
Vogl TJ; Hammerstingl R; Schnell B; Eibl-Eibesfeldt B; Peqios W; Lissner J
Bildgebung; 1992 Dec; 59(4):195-9. PubMed ID: 1292771
[TBL] [Abstract][Full Text] [Related]
28. Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation.
Pastor CM; Planchamp C; Pochon S; Lorusso V; Montet X; Mayer J; Terrier F; Vallee JP
Radiology; 2003 Oct; 229(1):119-25. PubMed ID: 12944603
[TBL] [Abstract][Full Text] [Related]
29. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.
Hamm B; Staks T; Mühler A; Bollow M; Taupitz M; Frenzel T; Wolf KJ; Weinmann HJ; Lange L
Radiology; 1995 Jun; 195(3):785-92. PubMed ID: 7754011
[TBL] [Abstract][Full Text] [Related]
30. T2-weighted magnetic resonance imaging of the liver: evaluation of the effect in signal intensity after Gd-EOB-DTPA enhancement.
Tamada T; Ito K; Yoshida K; Sone T; Murakami K; Kanki A; Watanabe S; Higashi H; Yamashita T
J Comput Assist Tomogr; 2010; 34(2):182-6. PubMed ID: 20351500
[TBL] [Abstract][Full Text] [Related]
31. Contrast agent Gd-EOB-DTPA (EOB·Primovist®) for low-field magnetic resonance imaging of canine focal liver lesions.
Yonetomi D; Kadosawa T; Miyoshi K; Nakao Y; Homma E; Hanazono K; Yamada E; Nakamura K; Ijiri A; Minegishi N; Maetani S; Hirayama K; Taniyama H; Nakade T
Vet Radiol Ultrasound; 2012; 53(4):371-80. PubMed ID: 22548505
[TBL] [Abstract][Full Text] [Related]
32. Enhanced liver MR: contrast agents and imaging strategy.
Runge VM; Kirsch JE; Wells JW; Awh MH; Bittner DF; Woolfolk CE
Crit Rev Diagn Imaging; 1993; 34(1-2):1-30. PubMed ID: 8216813
[TBL] [Abstract][Full Text] [Related]
33. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application.
Caudana R; Morana G; Pirovano GP; Nicoli N; Portuese A; Spinazzi A; Di Rito R; Pistolesi GF
Radiology; 1996 May; 199(2):513-20. PubMed ID: 8668804
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model.
Runge VM; Biswas J; Wintersperger BJ; Baumann SS; Jackson CB; Herborn CU; Patel T
Invest Radiol; 2006 Mar; 41(3):244-8. PubMed ID: 16481906
[TBL] [Abstract][Full Text] [Related]
35. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA.
Runge VM
J Comput Assist Tomogr; 1998; 22(4):643-50. PubMed ID: 9676461
[TBL] [Abstract][Full Text] [Related]
36. [Status and development of new clinical contrast media for MR diagnosis of liver diseases].
Rummeny EJ; Peters PE
Radiologe; 1992 May; 32(5):225-31. PubMed ID: 1635982
[TBL] [Abstract][Full Text] [Related]
37. MultiHance: help or hype?
Bartolozzi C; Spinazzi A
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S151-9. PubMed ID: 10608411
[TBL] [Abstract][Full Text] [Related]
38. Phantom and animal studies of a new hepatobiliary agent for MR imaging: comparison of Gd-DTPA-DeA with Gd-EOB-DTPA.
Yoshikawa K; Inoue Y; Akahane M; Shimada M; Itoh S; Seno A; Hayashi S
J Magn Reson Imaging; 2003 Aug; 18(2):204-9. PubMed ID: 12884333
[TBL] [Abstract][Full Text] [Related]
39. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI).
Motosugi U; Ichikawa T; Sou H; Sano K; Ichikawa S; Tominaga L; Araki T
J Magn Reson Imaging; 2009 Oct; 30(4):849-54. PubMed ID: 19787734
[TBL] [Abstract][Full Text] [Related]
40. Conspicuity of liver hemangiomas: short tau inversion recovery, T1, and T2 imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid.
Brody JM; Schafer L; Tung GA; Breuer J; Shamsi K
J Magn Reson Imaging; 2005 Apr; 21(4):391-7. PubMed ID: 15778951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
